General information about company		
Scrip code	506820	
NSE Symbol	ASTRAZEN	
MSEI Symbol	NOTLISTED	
ISIN	INE203A01020	
Name of the entity	ASTRAZENECA PHARMA INDIA LIMITED	
Date of start of financial year	01-04-2026	
Date of end of financial year	31-03-2027	
Reporting Quarter Type	Half Yearly	
Date of Quarter Ending	30-09-2026	
Type of company	Equity	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No	Disclosure related to acquisition of shares or voting rights in unlisted companies is not applicable to the Company in the reporting quarter.
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	Yes	
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	No	Disclosures of updates to ongoing tax litigation or disputes is not application to the Company for the quarter ended September 30, 2026.
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	No	The disclosure relating to loans/ Guarantees/ Comfort letters/ securities is not applicable to the Company.
Risk management committee	Applicable	
Market Capitalisation as per immediate previous Financial Year	Top 500 listed entities	
Is SCORE ID Available ?	Yes	
SCORE Registration ID	A00366	
Reason For No SCORE ID		
Type of Submission	Original	
Remarks (website dissemination)		
Remarks for Exchange (not for Website Dissemination)		

Annexure I

Annexure I to be submitted by listed entity on quarterly basis

I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory	Textual Information(1)
Whether the listed entity has a Regular Chairperson	Yes
Whether Chairperson is related to MD or CEO	No

Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Ms	SHILPA DIVEKAR NIRULA	AAHPD1574B	06619353	Non-Executive - Independent Director	Chairperson		30-11-1973
2	Ms	REVATHY ASHOK	ACLPR3951Q	00057539	Non-Executive - Independent Director	Not Applicable		16-01-1959
3	Ms	MONICA WIDHANI	AASPW5303N	07674403	Non-Executive - Independent Director	Not Applicable		18-01-1959
4	Mr	PRAVEEN RAO AKKINEPALLY	EUGPA4663F	11137771	Executive Director	Not Applicable		29-08-1974
5	Mr	ARUN KRISHNA	AHNPK0662Q	11876664	Non-Executive - Non Independent Director	Not Applicable		01-07-1980
6	Ms	HOOI BIEN CHUAH	ZZZZZ9999Z	10381891	Non-Executive - Non Independent Director	Not Applicable		17-01-1975
7	Ms	BHAVANA AGRAWAL	AFMPA5396L	10485441	Non-Executive - Non Independent Director	Not Applicable		04-11-1978

I. Composition of Board of Directors					
Disqualification of Directors under section 164 of the Companies Act, 2013					
Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status
1	No				Active
2	No				Active
3	No				Active
4	No				Active
5	No				Active
6	No				Active
7	No				Active

I. Composition of Board of Directors													
Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA		29-12-2021	29-12-2021		57.04	3	3	3	1			
2	NA		02-12-2016	02-12-2021		117.29	5	5	3	5			
3	NA		25-09-2024	25-09-2024		25.16	3	3	3	1			
4	NA		01-07-2025				1	0	1	0			
5	NA		10-08-2026				1	0	0	0			
6	NA		09-11-2023				1	0	1	1		Textual Information(2)	
7	NA		08-02-2024				1	0	0	0			

Text Block	
Textual Information(1)	Please note that Ms. Bhavana Agrawal (DIN: 10485441) ceased to be an Executive Director of the Company with effect from August 31, 2026 and was redesignated as a Non-Executive Director with effect from September 1, 2026. As the XBRL utility does not permit reporting of two designations against the same DIN, this note is being provided for clarification.
Textual Information(2)	Foreign National, Hence PAN is not applicable.

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	07674403	MONICA WIDHANI	Non-Executive - Independent Director	Chairperson	25-09-2024		
2	06619353	SHILPA DIVEKAR NIRULA	Non-Executive - Independent Director	Member	08-02-2022		
3	00057539	REVATHY ASHOK	Non-Executive - Independent Director	Member	30-05-2025		
4	10381891	HOOI BIEN CHUAH	Non-Executive - Non Independent Director	Member	08-02-2024		

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00057539	REVATHY ASHOK	Non-Executive - Independent Director	Chairperson	08-02-2022		
2	06619353	SHILPA DIVEKAR NIRULA	Non-Executive - Independent Director	Member	25-09-2024		
3	07674403	MONICA WIDHANI	Non-Executive - Independent Director	Member	11-03-2026		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	10381891	HOOI BIEN CHUAH	Non-Executive - Non Independent Director	Chairperson	26-05-2026		
2	06619353	SHILPA DIVEKAR NIRULA	Non-Executive - Independent Director	Member	30-05-2025		
3	11137771	PRAVEEN RAO AKKINEPALLY	Executive Director	Member	01-07-2025		
4	10485441	BHAVANA AGRAWAL	Non-Executive - Non Independent Director	Member	08-02-2024	31-08-2026	Textual Information(1)

Sr Text Block	
Textual Information(1)	Please note that Ms. Bhavana Agrawal (DIN: 10485441) ceased to be an Executive Director of the Company with effect from August 31, 2026 and was redesignated as a Non-Executive Director with effect from September 1, 2026. Consequently, she ceased to be a member of the Stakeholder Relationship Committee w.e.f. September 1, 2026.

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	07674403	MONICA WIDHANI	Non-Executive - Independent Director	Chairperson	25-09-2024		
2	11137771	PRAVEEN RAO AKKINEPALLY	Executive Director	Member	01-07-2025		
3	10485441	BHAVANA AGRAWAL	Non-Executive - Non Independent Director	Member	08-02-2024	31-08-2026	Textual Information(1)
4	99999999	AMARPREET KAUR AHUJA	Country HR Director	Member	03-08-2020		Textual Information(2)

Sr Text Block	
Textual Information(1)	Please note that Ms. Bhavana Agrawal (DIN: 10485441) ceased to be an Executive Director of the Company with effect from August 31, 2026 and was redesignated as a Non-Executive Director with effect from September 1, 2026. Consequently, she ceased to be a member of the Risk Management Committee w.e.f. September 1, 2026.
Textual Information(2)	Ms. Amarpreet Kaur Ahuja is not a Director, hence DIN is not available.

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	10381891	HOOI BIEN CHUAH	Non-Executive - Non Independent Director	Chairperson	08-02-2024		
2	00057539	REVATHY ASHOK	Non-Executive - Independent Director	Member	02-02-2017		
3	11137771	PRAVEEN RAO AKKINEPALLY	Executive Director	Member	01-07-2025		

Other Committee						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

Annexure 1

Annexure 1

III. Meeting of Board of Directors

Disclosure of notes on meeting of board of directors explanatory								
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	26-05-2026				Yes	6	6	3
2		10-08-2026	75		Yes	6	6	3

Annexure 1

IV. Meeting of Committees

Disclosure of notes on meeting of committees explanatory										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	26-05-2026				Yes	4	4	3	0
2	Audit Committee	10-08-2026	75			Yes	4	4	3	0
3	Audit Committee	06-10-2026	56			Yes	4	2	2	0
4	Nomination and remuneration committee	26-05-2026				Yes	3	3	3	0
5	Nomination and remuneration committee	10-08-2026	75			Yes	3	3	3	0
6	Corporate Social Responsibility Committee	26-05-2026				Yes	3	3	1	0

Annexure 1

IV. Meeting of Committees

Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Risk Management Committee	10-08-2026	75			Yes	3	3	1	1

Annexure 1		
V. Affirmations		
Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

Annexure 1		
Sr	Subject	Compliance status
1	Name of signatory	Tanya Sanish
2	Designation	Company Secretary and Compliance Officer

Affirmations on Compliance Requirements for AGM (applicable only for the first half-year filing i.e., 2nd quarter)				
I. Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, BRSR & BRSR core, if applicable, displayed on website	46(2)	Yes	
2	Presence of Chairperson of Audit Committee at the Annual General Meeting	18(1)(d)	Yes	
3	Presence of Chairperson of the nomination and remuneration committee at the annual general meeting	19(3)	Yes	
4	Presence of Chairperson of the Stakeholder Relationship committee at the annual general meeting	20(3)	Yes	
5	Disclosure of the Secretarial Audit Report of the listed entity and the material subsidiaries in the Annual Report	24A(1)	Yes	
6	Compliance with the conditions laid down for Secretarial Auditor or the person signing the Secretarial Compliance Report	24A(1A), 24A(1B), 24A(1C)	Yes	
7	Submission of Annual Secretarial Compliance Report	24A(2)	Yes	
8	Whether "Corporate Governance Report" disclosed in Annual Report	34(3) read with para C of Schedule V	Yes	
Any other information to be provided				

Annexure III		
1	Name of signatory	Tanya Sanish
2	Designation	Company Secretary and Compliance Officer

Details of Cyber security incidence		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter		No
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		
Sr.	Date of the event	Brief details of the event

Signatory Details	
Name of signatory	Tanya Sanish
Designation of person	Company Secretary and Compliance Officer
Place	Mumbai
Date	27-10-2026

Investor Grievance Details	
No. of investor complaints pending at the beginning of Quarter	2
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	2
No. of investor complaints those remaining unresolved at the end of the Quarter	0

Disclosure of Imposition of Fine or Penalty The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:

Any Other Information for Disclosure of Imposition of Fine or Penalty					
Sr. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
1	National Pharmaceutical Pricing Authority	Demand Notice issued by the NPPA for alleged overcharging under the Drugs (Prices Control) Order, 2013 ('DPCO, 2013') of Rs. 79,97,457/- inclusive of interest calculated upto August 10, 2026.	27-07-2026	NPPA has alleged that AstraZeneca Pharma India Ltd. sold/marketed Betaloc-50 (Metoprolol 50 mg tablets) at an MRP higher than the ceiling price notified under DPCO, 2013, and has not implemented the revised ceiling price on stocks available in the market from the notifications i.e. Notification S.O. 644(E) dated 02.03.2016 and Notification S.O. 1352(E) dated 02.06.2016 in respect of Betaloc-50 tablets. This has allegedly resulted in overcharging during the period of June to July 2016, for which NPPA has demanded recovery of the overcharged amount along with applicable interest to be paid within 30 days from the date of receipt of the Notice.	Demand of Rs. 79,97,457/- inclusive of interest calculated upto August 10, 2026.
2	National Pharmaceutical Pricing Authority	Demand Notice issued by the NPPA for alleged overcharging under the Drugs (Prices Control) Order, 2013 ('DPCO, 2013') of Rs. 1,48,65,83,590/- inclusive of interest calculated upto August 20, 2026.	29-07-2026	Further to a show cause notice dated September 11, 2025, the Company has received a demand notice from NPPA on July 29, 2026, in relation to Symbicort Turbuhaler 160/4.5 (Inhaler). NPPA has alleged overcharging for the period from May 2016 to November 2025 under DPCO, 2013 and has demanded Rs. 1,48,65,83,590/-, including interest, payable within 30 days from receipt of the notice. The Company is currently evaluating the demand notice and appropriate legal actions.	Rs. 1,48,65,83,590/- inclusive of interest calculated upto August 20, 2026.
3	Hon'ble High Court of Delhi	Order dated August 24, 2026 passed in W.P.(C) 12314/2026 & CM APPL. 57158 59/2026, titled AstraZeneca Pharma India Limited v. National Pharmaceutical Pricing Authority, Department of Pharmaceuticals & Anr., the NPPA demand notice dated July 27, 2026.	24-08-2026	NPPA has alleged that AstraZeneca Pharma India Ltd. sold/marketed Betaloc-50 (Metoprolol 50 mg tablets) at an MRP higher than the ceiling price notified under DPCO, 2013, and has not implemented the revised ceiling price on stocks available in the market from the notifications i.e. Notification S.O. 644(E) dated 02.03.2016 and Notification S.O. 1352(E) dated 02.06.2016 in respect of Betaloc-50 tablets. This has allegedly resulted in overcharging during the period of June to July 2016, for which NPPA has demanded recovery of the overcharged amount along with applicable interest The Company challenged the Demand Notice before the Hon'ble High Court of Delhi. Vide order dated August 24, 2026, the Hon'ble High Court of Delhi has stayed the operation of the Demand Notice until the next date of hearing i.e. February 10, 2027, subject to the Company depositing 15% of the amount mentioned in the Demand Notice with the Registrar General, Delhi High Court. The Company is taking necessary steps in this connection.	15% of the amount mentioned in the Demand Notice.
4	Registrar of Companies, Bengaluru,	Order for adjudication of penalty under Section 454 of the Companies Act,	17-09-2026	The Company had appointed Dr. Sanjeev Kumar Panchal as Managing Director with effect from January 1, 2023. Form MR-2,	The order imposes a penalty of Rs.1,88,000/- on

	Karnataka ('ROC')	2013 in respect of violation of Section 201 of the Companies Act, 2013 read with Rule 7(3) of the Companies (Appointment and Remuneration) Rules, 2014 relating to delay in filing Form MR-2. The order imposes a penalty of Rs.1,88,000/- on the Company and Rs. 50,000/- each on the erstwhile concerned officers - in - default.		which was required to be filed within the prescribed timeline, was filed with a delay. The Company, in its representations, explained that the delay in filing was on account of technical glitches experienced on the filing portal of the Ministry of Corporate Affairs ('MCA'), whereby Dr. Sanjeev Kumar Panchal's DIN, was erroneously reflected as inactive due to alleged non-filing of DIR-3 KYC, despite inapplicability of this requirement at the time. The DIN was activated in August 2023 following sustained follow-up efforts, after which requisite filings were completed. The ROC has now passed an abovementioned order in the matter.	the Company and Rs. 50,000/- each on the erstwhile concerned officers - in - default.